Hemispherian AS

Hemispherian is developing a breakthrough class of cancer drugs that target the DNA damage response by activating the TET2 enzyme. Their lead asset, GLIX1, has shown remarkable efficacy in animal models, curing aggressive cancers like glioblastoma, with proven safety in toxicology studies.

GLIX1 also enhances the effectiveness of PARP inhibitors, expanding their use to a wider range of cancers, including HR-proficient ones. The FDA has confirmed that GLIX1 is ready for clinical trials, and the company has the support of leading clinicians from Stanford, Northwestern, and Mount Sinai Hospital.

Hemispherian is raising a €20M Series A to fund clinical development, offering a unique opportunity for investors to drive this disruptive cancer therapeutic technology while capturing a large share of a multi-billion dollar market by 2028. Join Hemispherian in changing the future of cancer treatment.